Interim results from Mediclinic show that minority shareholders are probably getting a fair deal from the Remgro-led consortium that made an offer of £5.04 per share for their shares. Based on the latest results, the offer equates to a price-earnings ratio of 22 times, while shareholders are bound to appreciate the advantages of having a bird in the hand rather than seeing them flying around the bush.
The scheme of arrangement has received approval from all the relevant authorities in different countries, except in SA – the only uncertainty remaining for shareholders.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: